Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
2.960
-0.030 (-1.00%)
At close: Aug 3, 2026, 4:00 PM EDT
2.980
+0.020 (0.68%)
After-hours: Aug 3, 2026, 6:16 PM EDT
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
145.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caribou Biosciences | 11.20M |
| Cibus | 4.29M |
| Korro Bio | 3.84M |
| Milestone Pharmaceuticals | 1.78M |
| Kazia Therapeutics | 1.27M |
| YD Bio | 510.36K |
ENTX News
- 3 days ago - Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 5 days ago - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE - PRNewsWire
- 7 days ago - Entera Bio announces $275M private placement - TheFly
- 7 days ago - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement - GlobeNewsWire
- 5 weeks ago - Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewsWire
- 6 weeks ago - Entera Bio gets FDA feedback on registrational protocol for EB613 - TheFly
- 6 weeks ago - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 6 weeks ago - Entera Bio and Opko Health present preclinical data for oral peptides - TheFly